首页|Neoantigen cancer vaccines:a new star on the horizon

Neoantigen cancer vaccines:a new star on the horizon

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Immunotherapy represents a promising strategy for cancer treatment that utilizes immune cells or drugs to activate the patient's own immune system and eliminate cancer cells.One of the most exciting advances within this field is the targeting of neoantigens,which are peptides derived from non-synonymous somatic mutations that are found exclusively within cancer cells and absent in normal cells.Although neoantigen-based therapeutic vaccines have not received approval for standard cancer treatment,early clinical trials have yielded encouraging outcomes as standalone monotherapy or when combined with checkpoint inhibitors.Progress made in high-throughput sequencing and bioinformatics have greatly facilitated the precise and efficient identification of neoantigens.Consequently,personalized neoantigen-based vaccines tailored to each patient have been developed that are capable of eliciting a robust and long-lasting immune response which effectively eliminates tumors and prevents recurrences.This review provides a concise overview consolidating the latest clinical advances in neoantigen-based therapeutic vaccines,and also discusses challenges and future perspectives for this innovative approach,particularly emphasizing the potential of neoantigen-based therapeutic vaccines to enhance clinical efficacy against advanced solid tumors.

Immunotherapyneoantigen cancer vaccinesolid tumorshigh-throughput sequencingbioinformaticsPDOsAIHLATCR

Xiaoling Li、Jian You、Liping Hong、Weijiang Liu、Peng Guo、Xishan Hao

展开 >

Cell Biotechnology Laboratory,Tianjin Cancer Hospital Airport Hospital,Tianjin 300308,China

National Clinical Research Center for Cancer,Tianjin 300060,China

Haihe Laboratory of Synthetic Biology,Tianjin 300090,China

Department of Thoracic Oncology,Tianjin Cancer Hospital Airport Hospital,Tianjin 300308,China

Department of Thoracic Oncology Surgery,Tianjin Medical University Cancer Institute&Hospital,Tianjin 300060,China

Tianjin Medical University Cancer Institute&Hospital,Tianjin 300060,China

展开 >

National Clinical Research Center Cancer FundHaihe Laboratory of Synthetic Biology

22HHSWSS00004

2024

10.20892/j.issn.2095-3941.2023.0395

癌症生物学与医学(英文版)
中国抗癌协会

癌症生物学与医学(英文版)

CSTPCD
影响因子：1.07
ISSN：2095-3941
年,卷(期)：2024.21(4)
  • 208